health
February 23, 2026
FDA moves to facilitate personalized therapies for rare diseases
The Food and Drug Administration is making it possible for pharmaceutical companies to produce bespoke medicines for individual patients, an effort to revolutionize the standard of care for rare diseases.
TL;DR
- The FDA is updating approval standards for personalized genetic medicines.
- A new pathway will be created for therapies targeting patient groups too small for traditional clinical trials.
- The guidance offers clearer rules for developing genome-editing and RNA-based drugs for diseases caused by unique genetic mutations.
- Companies must justify why randomized trials are not feasible and collect real-world evidence post-approval.
- The initiative was inspired by the successful treatment of an infant with an ultra-rare enzyme deficiency using gene editing therapy.
Continue reading the original article